Form 4: TENX Director Doogan Acquires 30,000 Stock Options

TENAX THERAPEUTICS, INC. Director Declan Doogan reported the acquisition of 30,000 stock options and beneficial ownership of 2,274 common shares.

Summary

• Declan Doogan, a Director of TENAX THERAPEUTICS, INC., directly beneficially owns 2,274 shares of common stock.
• On January 9, 2026, Mr. Doogan acquired 30,000 stock options with an exercise price of $13.30 per share.
• These newly acquired options become exercisable on January 9, 2027, and are set to expire on January 9, 2036.
• Following this transaction, Mr. Doogan also beneficially owns additional stock options, including: 4 options with an exercise price of $3,200, 4 options with an exercise price of $992, 100,000 options with an exercise price of $5.94, and 80,000 options with an exercise price of $5.75.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally viewed as a minor positive signal, indicating confidence in the company's future prospects. However, a Form 4 primarily reports transactions and does not provide comprehensive financial or operational details to warrant a higher sentiment score.

Positives

• The acquisition of 30,000 stock options by a Director can signal management's confidence in the future performance and growth potential of TENAX THERAPEUTICS, INC.

Risks

• The value of stock options is inherently tied to the future stock price performance of TENAX THERAPEUTICS, INC., meaning they carry market risk.
• If the stock price does not appreciate above the exercise price, the options may expire worthless.

Future Outlook

This Form 4 filing is a disclosure of insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a routine insider transaction report and does not provide specific details that allow for a direct analysis of broader industry trends or competitive positioning. Insider buying of options can sometimes be interpreted as a positive signal within the biotechnology or pharmaceutical industry, indicating confidence in future drug development or market potential.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock options as a positive indicator of management's belief in the company's future value, potentially boosting investor confidence.

Next Steps

• The newly acquired stock options will become exercisable on January 9, 2027.

Key Dates

Keywords

TENAX THERAPEUTICS, TENX, Form 4, Insider Transaction, Stock Options, Director, Beneficial Ownership, Declan Doogan